Hyper Corporation

Hyper Corporation Financing Cash Flow

The Net Financing Cash Flow of Hyper Corporation (065650.KQ) as of Oct 31, 2026 is 59.67 B KRW. In the previous year, Net Financing Cash Flow was -421.18 M KRW — a change of -14,267.56% (higher).

Financing Cash Flow

59.67 BKRW

YoY

-14,267.56%

Last updated:

Net Financing Cash Flow of Hyper Corporation is 2024 59.67 B KRW. Net Financing Cash Flow of Hyper Corporation was 2023 -421.18 M KRW. It decreases by -14,267.56% higher compared to the previous year.

The Hyper Corporation Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
10.80 B KRW
Jan 1, 2018
27.43 M KRW
Jan 1, 2019
26.65 M KRW
Jan 1, 2020
26.93 B KRW
Jan 1, 2021
10.60 B KRW
Jan 1, 2022
20.53 B KRW
Jan 1, 2023
-421.18 M KRW
Jan 1, 2024
59.67 B KRW
The Hyper Corporation Financing Cash Flow history
YEARFinancing Cash FlowYoY
59.67 BKRW-14,267.56%
-421.18 MKRW-102.05%
20.53 BKRW+93.75%
10.60 BKRW-60.64%
26.93 BKRW+100,940.13%
26.65 MKRW-2.83%
27.43 MKRW-99.75%
10.80 BKRW0.00%
10.80 BKRW+80.58%
5.98 BKRW0.00%
5.98 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyper Corporation Stock analysis

What does Hyper Corporation do? Hyper Corporation Inc generates revenue through the Information Technology Business segment, which manufactures and sells mouses, monitors, televisions, routers, and game devices, while also operating Internet portals and specialized sites. The New Drug Business segment develops and sells non narcotic analgesics, Alzheimer's treatments, and Alzheimer's dementia diagnosis kits. The company's IT products are purchased by consumers and businesses seeking technology solutions, while the pharmaceutical products target healthcare providers and patients requiring pain management and cognitive health support. The Information Technology Business segment benefits from the sale of hardware devices and digital content services, with Internet portals and specialized sites driving user engagement and advertising revenue. The New Drug Business segment focuses on medical solutions for chronic conditions, serving both institutional and individual markets through direct sales channels. Both segments operate under the same corporate structure, leveraging the company's existing infrastructure for product development and distribution. Hyper Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyper Corporation stock

Net Financing Cash Flow of Hyper Corporation is 59.67 B KRW in 2024.

Net Financing Cash Flow of Hyper Corporation changed from -421.18 M KRW to 59.67 B KRW, representing a -14,267.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Hyper Corporation since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Hyper Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hyper Corporation

All Key Metrics — Hyper Corporation